Mizuho Lowers DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $14.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price decreased by research analysts at Mizuho from $16.00 to $14.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s price target would indicate a potential upside of 23.84% from the company’s current price.

XRAY has been the topic of several other reports. Wells Fargo & Company raised their price objective on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. UBS Group dropped their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Citigroup initiated coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Monday, April 20th. Finally, Robert W. Baird increased their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $13.73.

DENTSPLY SIRONA Stock Down 0.6%

Shares of XRAY opened at $11.31 on Wednesday. The firm has a 50 day simple moving average of $12.14 and a two-hundred day simple moving average of $12.02. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. DENTSPLY SIRONA has a one year low of $9.85 and a one year high of $17.18. The company has a market cap of $2.26 billion, a P/E ratio of -3.79, a P/E/G ratio of 1.32 and a beta of 0.93.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. During the same period in the prior year, the business posted $0.43 EPS. The company’s revenue for the quarter was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts forecast that DENTSPLY SIRONA will post 1.43 EPS for the current fiscal year.

Insider Activity

In other DENTSPLY SIRONA news, Director Gregory T. Lucier acquired 27,555 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was acquired at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the acquisition, the director directly owned 27,555 shares in the company, valued at $392,383.20. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James D. Forbes bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at $124,800. This trade represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 70,000 shares of company stock valued at $956,437 over the last quarter. Corporate insiders own 0.52% of the company’s stock.

Institutional Trading of DENTSPLY SIRONA

Several institutional investors have recently modified their holdings of XRAY. Bank of New York Mellon Corp raised its position in DENTSPLY SIRONA by 14.1% during the 1st quarter. Bank of New York Mellon Corp now owns 1,400,200 shares of the medical instruments supplier’s stock worth $16,242,000 after purchasing an additional 173,151 shares during the last quarter. Sanctuary Advisors LLC increased its stake in shares of DENTSPLY SIRONA by 30.6% in the first quarter. Sanctuary Advisors LLC now owns 38,179 shares of the medical instruments supplier’s stock valued at $443,000 after buying an additional 8,953 shares during the period. Calamos Wealth Management LLC bought a new position in shares of DENTSPLY SIRONA during the first quarter worth about $286,000. Calamos Advisors LLC bought a new position in shares of DENTSPLY SIRONA during the first quarter worth about $286,000. Finally, Principal Financial Group Inc. lifted its stake in shares of DENTSPLY SIRONA by 3.8% in the first quarter. Principal Financial Group Inc. now owns 445,630 shares of the medical instruments supplier’s stock worth $5,169,000 after acquiring an additional 16,516 shares during the period. Institutional investors own 95.70% of the company’s stock.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Revenue beat and top-line strength: Dentsply reported Q1 net sales of $880M vs. consensus ~$842M, surprising on the top line even as EPS missed, supporting near-term revenue momentum. Dentsply Sirona beats Q1 sales expectations
• Positive Sentiment: New product — AI-enabled diagnostic: Company launched Smart View?Detect (FDA-cleared, CE-marked), an AI diagnostic aid for CBCT scans — a potential multi-market growth driver for imaging and software revenue over time. Smart View – Detect launch
• Positive Sentiment: U.S. distribution expansion and early commercial traction: Enhanced agreement with Atlanta Dental Supply (adds a channel for connected technology) and first CEREC install under new Benco deal signal expanding go-to-market reach for consumables and equipment. Distribution expansion with Atlanta Dental Supply
• Neutral Sentiment: FY?2026 guidance roughly in-line on EPS but revenue range mixed vs Street: Company gave FY EPS of $1.40–$1.50 (Street ~1.43) and revenue $3.5–3.6B (slightly below some estimates) — guidance reduces uncertainty but isn’t a strong catalyst either way. Q1 results & guidance (press release/slide deck)
• Neutral Sentiment: Analyst positioning: Brokers show an average “Hold” and coverage notes stabilization but not a clear re-rating event yet — suggests limited near-term upside until margin/growth trends clarify. Average recommendation of “Hold”
• Negative Sentiment: EPS miss and GAAP loss: Reported adjusted EPS $0.27 (miss by $0.01) and GAAP net loss per share ($0.05); EPS is down from $0.43 year?ago, putting pressure on near-term sentiment and valuation. Q1 EPS miss
• Negative Sentiment: Margin pressure, tariffs and transformation costs remain a concern: Management flagged U.S. softness, tariff headwinds and transformation costs that weigh on margins — investors will watch margin recovery and working capital / debt reduction execution. Analyst preview: margin & tariff risks

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.